Replies to post #186390 on Biotech Values

[DewDiligence]

ENTA—what about HBV, which...is quite a problem in Europe, and for which there is still no cure. Could their drugs reach that?

DAAs for HCV don’t work against HBV (and vice-versa); ENTA has never revealed any interest in HBV, so I presume they’re not pursing it.

The premiere developer of new drugs for HBV is probably the recently announced OnCore-TKMR combination (#msg-109820030, #msg-109841768).

[DewDiligence]

Could such a combination potentially reach the ~7% of HCV sufferers not being cured now by GILD or ABBV?

From where you are getting that 7% number? Please clarify.